News
XCUR
4.030
-5.40%
-0.230
Weekly Report: what happened at XCUR last week (0202-0206)?
Weekly Report · 3h ago
Exicure announces publication of results from Phase 2 study of burixafor
TipRanks · 4d ago
Exicure kündigt erfolgreiche Phase-2-Studie mit Burixafor zur schnellen Stammzellmobilisierung bei Multiplem Myelom und Lymphom an
Reuters · 4d ago
Exicure Reports Phase 2 Success for Burixafor in Rapid Stem Cell Mobilization for Transplant Patients
Reuters · 4d ago
Weekly Report: what happened at XCUR last week (0126-0130)?
Weekly Report · 02/02 09:00
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 01/27 21:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 01/26 17:05
Weekly Report: what happened at XCUR last week (0119-0123)?
Weekly Report · 01/26 09:00
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up
TipRanks · 01/24 13:01
Exicure Achieves Milestone in Burixafor Phase 2 Program
TipRanks · 01/22 21:44
Exicure Achieves Milestone in Collaboration with GPCR Therapeutics
Reuters · 01/22 21:29
Major Exicure Stakeholder Makes Bold Move With Large Share Sale
TipRanks · 01/22 02:02
Exicure HiTron Inc. Reports Disposal of Exicure Inc. Common Shares
Reuters · 01/21 17:46
Exicure to present data from burixafor Phase 2 trial at 2026 Tandem Meetings
TipRanks · 01/21 12:15
Exicure Reports Positive Phase 2 Results for Burixafor in Multiple Myeloma Stem Cell Mobilization
Reuters · 01/21 12:00
Major Exicure Stakeholder Makes a Big Move With a Multi-Million Dollar Stock Sale
TipRanks · 01/21 02:03
Weekly Report: what happened at XCUR last week (0112-0116)?
Weekly Report · 01/19 09:00
Weekly Report: what happened at XCUR last week (0105-0109)?
Weekly Report · 01/12 09:00
Exicure HiTron Inc. Reports Disposal of Exicure Inc. Common Shares
Reuters · 01/09 01:43
More
Webull provides a variety of real-time XCUR stock news. You can receive the latest news about Exicure Inc through multiple platforms. This information may help you make smarter investment decisions.
About XCUR
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.